Meridian Bioscience (VIVO) Tops Q2 EPS by 3c

Meridian Bioscience (NASDAQ: VIVO) reported Q2 EPS of $0.19, $0.03 better than the analyst estimate of $0.16. Revenue for the quarter came in at $50.2 million versus the consensus estimate of $51.74 million.

For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Stifel Starts Victrex Plc. (VCT:LN) (VTXPF) at Buy
• Primoris cuts 2026 outlook on renewables cost overruns, COO exits